MLM Medical Labs’ IVDR-validated LDT for the pTau217/β-amyloid ratio is now in active use in a European clinical trial, supporting biomarker-driven patient selection.
Cytespace Africa Laboratories, an MLM Company, announces a major infrastructure expansion in South Africa. By localizing kit building and specimen management, Cytespace is reducing logistics complexity and costs for global sponsors expanding into the growing Sub-Saharan African clinical trials market.
Clinical trials cost billions, yet promising drugs still fail for preventable reasons. Discover how the wrong laboratory partner can quietly derail a study—and why choosing the right one matters.
Cytespace Africa Laboratories, a CAP-accredited MLM Medical Labs company, has tripled its molecular testing capacity to support faster, high-throughput clinical trials across Sub-Saharan Africa.
MLM Medical Labs leads in IVDR LDT Alzheimer’s biomarker testing with a validated Lumipulse® pTau217/Beta-Amyloid 1-42 plasma assay, enabling reliable, regulatory-compliant data to support global Alzheimer’s clinical trials.
Sponsors of global clinical trials don’t need another oversized, bureaucratic lab — they need a right-sized, science-first partner. Discover how MLM Medical Labs delivers proactive support, direct scientific access, and operational excellence across every phase of complex clinical trials worldwide.
Infectious disease trials demand speed, precision, and regional expertise. This article explores the top operational challenges sponsors face in Sub-Saharan Africa—and how MLM Medical Labs and Cytespace Africa Laboratories deliver a purpose-built, lab-integrated solution to accelerate timelines and improve data integrity.
MLM Medical Labs Approved by French Ministry for R&D and Innovation Tax Incentives Decision strengthens MLM’s standing as a proven and preferred partner in European
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
MLM Medical Labs – Germany Awarded 6th Consecutive CAP Accreditation for Service Excellence MÖNCHENGLADBACH, GERMANY – March 11, 2025 MLM Medical Labs (MLM), a global
